Last reviewed 2026-05-14 · How we verify

Oral Suspension Tedizolid Phosphate

Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

At a glance

Mechanism of action

Tedizolid phosphate is rapidly converted to its active form, tedizolid, which binds to the bacterial 50S ribosomal subunit and prevents peptide bond formation, thereby inhibiting protein synthesis. This mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens. The oxazolidinone class represents a unique antibiotic mechanism distinct from other protein synthesis inhibitors.

Approved indications

• Acute bacterial skin and skin structure infections (ABSSSI)
• Community-acquired bacterial pneumonia (CABP)

Common side effects

• Nausea
• Diarrhea
• Headache
• Vomiting
• Peripheral neuropathy
• Optic neuropathy

Key clinical trials

• A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
• A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014) (PHASE1)
• A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) (PHASE1)
• A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) (PHASE1)
• A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Oral Suspension Tedizolid Phosphate CI brief — competitive landscape report
• Oral Suspension Tedizolid Phosphate updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI